Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion

被引:233
|
作者
Lundholm, Marie [1 ]
Schroder, Mona [1 ]
Nagaeva, Olga [2 ]
Baranov, Vladimir [2 ]
Widmark, Anders [3 ]
Mincheva-Nilsson, Lucia [2 ]
Wikstrom, Pernilla [1 ]
机构
[1] Umea Univ, Dept Med Biosci, Umea, Sweden
[2] Umea Univ, Dept Clin Microbiol, Umea, Sweden
[3] Umea Univ, Dept Radiat Sci, Umea, Sweden
来源
PLOS ONE | 2014年 / 9卷 / 09期
基金
瑞典研究理事会;
关键词
CANCER-PATIENTS; LIGANDS; MICROVESICLES; IMMUNORECEPTOR; APOPTOSIS; VESICLES; RECEPTOR; RELEASE; IMMUNOSURVEILLANCE; CYTOTOXICITY;
D O I
10.1371/journal.pone.0108925
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumor-derived exosomes, which are nanometer-sized extracellular vesicles of endosomal origin, have emerged as promoters of tumor immune evasion but their role in prostate cancer (PC) progression is poorly understood. In this study, we investigated the ability of prostate tumor-derived exosomes to downregulate NKG2D expression on natural killer (NK) and CD8(+) T cells. NKG2D is an activating cytotoxicity receptor whose aberrant loss in cancer plays an important role in immune suppression. Using flow cytometry, we found that exosomes produced by human PC cells express ligands for NKG2D on their surface. The NKG2D ligand-expressing prostate tumor-derived exosomes selectively induced downregulation of NKG2D on NK and CD8(+) T cells in a dose-dependent manner, leading to impaired cytotoxic function in vitro. Consistent with these findings, patients with castration-resistant PC (CRPC) showed a significant decrease in surface NKG2D expression on circulating NK and CD8(+) T cells compared to healthy individuals. Tumor-derived exosomes are likely involved in this NKG2D downregulation, since incubation of healthy lymphocytes with exosomes isolated from serum or plasma of CRPC patients triggered downregulation of NKG2D expression in effector lymphocytes. These data suggest prostate tumor-derived exosomes as down-regulators of the NKG2D-mediated cytotoxic response in PC patients, thus promoting immune suppression and tumor escape.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells
    Qi, Yuan-Ying
    Lu, Chao
    Ju, Ying
    Wang, Zi-E
    Li, Yuan-Tang
    Shen, Ya-Juan
    Lu, Zhi-Ming
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (18) : 7857 - 7861
  • [32] Unraveling the expression of microRNA-27a*& NKG2D in peripheral blood mononuclear cells and natural killer cells of pediatric systemic lupus erythematosus patients
    Sourour, Shady K.
    Aboelenein, Heba R.
    Elemam, Noha M.
    Abdelhamid, Amira K.
    Salah, Samia
    Abdelaziz, Ahmed I.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (09) : 1237 - 1246
  • [33] NKG2D stimulation of CD8+ T cells during priming promotes their capacity to produce cytokines in response to viral infection in mice
    Kavazovic, Inga
    Lenartic, Maja
    Jelencic, Vedrana
    Jurkovic, Slaven
    Lemmermann, Niels A. W.
    Jonjic, Stipan
    Polic, Bojan
    Wensveen, Felix M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 47 (07) : 1123 - 1135
  • [34] NKG2D+ IFN-γ+ CD8+ T Cells Are Responsible for Palladium Allergy
    Kawano, Mitsuko
    Nakayama, Masafumi
    Aoshima, Yusuke
    Nakamura, Kyohei
    Ono, Mizuho
    Nishiya, Tadashi
    Nakamura, Syou
    Takeda, Yuri
    Dobashi, Akira
    Takahashi, Akiko
    Endo, Misato
    Ito, Akiyo
    Ueda, Kyosuke
    Sato, Naoki
    Higuchi, Shigehito
    Kondo, Takeru
    Hashimoto, Suguru
    Watanabe, Masamichi
    Watanabe, Makoto
    Takahashi, Tetsu
    Sasaki, Keiichi
    Nakamura, Masanori
    Sasazuki, Takehiko
    Narushima, Takayuki
    Suzuki, Ryuji
    Ogasawara, Kouetsu
    PLOS ONE, 2014, 9 (02):
  • [35] SAP Protein-Dependent Natural Killer T-like Cells Regulate the Development of CD8+ T Cells with Innate Lymphocyte Characteristics
    Verykokakis, Mihalis
    Boos, Markus D.
    Bendelac, Albert
    Kee, Barbara L.
    IMMUNITY, 2010, 33 (02) : 203 - 215
  • [36] Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer
    Shen, Yajuan
    Lu, Chao
    Tian, Wenjun
    Wang, Laicheng
    Cui, Bin
    Jiao, Yulian
    Ma, Chunyan
    Ju, Ying
    Zhu, Ling
    Shao, Chunhong
    Liu, Xinqi
    Wang, Jian
    Zhang, Bingchang
    Lu, Zhiming
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (04) : 1285 - 1290
  • [37] Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells
    Schwinn, Nicole
    Vokhminova, Daria
    Sucker, Antje
    Textor, Sonja
    Striegel, Sandra
    Moll, Iris
    Nausch, Norman
    Tuettenberg, Jochen
    Steinle, Alexander
    Cerwenka, Adelheid
    Schadendorf, Dirk
    Paschen, Annette
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (07) : 1594 - 1604
  • [38] DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells
    Fernandez-Sanchez, Alba
    Baragano Raneros, Aroa
    Carvajal Palao, Reyes
    Sanz, Ana B.
    Ortiz, Alberto
    Ortega, Francisco
    Suarez-Alvarez, Beatriz
    Lopez-Larrea, Carlos
    EPIGENETICS, 2013, 8 (01) : 66 - 78
  • [39] CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells
    Chen, Zhangguo
    Chen, Lanfen
    Baker, Kristi
    Olszak, Torsten
    Zeissig, Sebastian
    Huang, Yu-Hwa
    Kuo, Timothy T.
    Mandelboim, Ofer
    Beauchemin, Nicole
    Lanier, Lewis L.
    Blumberg, Richard S.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (13): : 2633 - 2640
  • [40] Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8+ invariant natural killer T cells
    Ghnewa, Yasmeen G.
    O'Reilly, Vincent P.
    Vandenberghe, Elisabeth
    Browne, Paul V.
    McElligott, Anthony M.
    Doherty, Derek G.
    CLINICAL IMMUNOLOGY, 2017, 183 : 91 - 98